Ikena Oncology, Inc.

( )
IKNA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.33%161.910.0%$1904.75m
OCGNOcugen, Inc. 1.26%8.860.0%$1093.41m
BNTXBioNTech SE 0.55%193.820.0%$877.28m
AMGNAmgen, Inc. 0.00%251.381.3%$740.91m
NVAXNovavax, Inc. 1.00%133.0079.8%$578.20m
SNSSSunesis Pharmaceuticals, Inc. 0.00%7.680.7%$536.86m
GILDGilead Sciences, Inc. -0.18%68.411.0%$503.67m
REGNRegeneron Pharmaceuticals, Inc. 0.00%516.622.7%$432.65m
ALXNAlexion Pharmaceuticals, Inc. 0.00%173.492.0%$412.31m
VRTXVertex Pharmaceuticals, Inc. -1.00%214.911.9%$308.42m
ILMNIllumina, Inc. 0.00%381.033.5%$302.74m
BIIBBiogen, Inc. 0.00%280.211.7%$269.43m
VXRTVaxart, Inc. -2.42%6.450.0%$234.96m
CRSPCRISPR Therapeutics AG 0.05%106.690.6%$171.49m
BNGOBionano Genomics, Inc. -2.78%5.250.0%$158.24m

Company Profile

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.